angioplasty

To discontinue clopidogrel after a year of infarction can be risky

Reference: Charlot et al. European Heart Journal 2012 (in press). International guideline recommendations approve giving dual antiplatelet therapy for a period of not less than 12 months after acute myocardial infarction. However, the benefit is unknown if the therapy is extended beyond 12 months. Perhaps its extension could be particularly useful in patients receiving pharmacological<a href="https://solaci.org/en/2012/10/01/to-discontinue-clopidogrel-after-a-year-of-infarction-can-be-risky/" title="Read more" >...</a>

Renal failure in acute myocardial infarction

Reference:&nbsp;Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as<a href="https://solaci.org/en/2012/09/01/renal-failure-in-acute-myocardial-infarction/" title="Read more" >...</a>

Hyperglycemia on admission, an excess risk for infarction

Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with<a href="https://solaci.org/en/2012/09/01/hyperglycemia-on-admission-an-excess-risk-for-infarction/" title="Read more" >...</a>

In patients with stroke history, Ticagrelor is superior to Clopidogrel

James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:<a href="https://solaci.org/en/2012/09/01/in-patients-with-stroke-history-ticagrelor-is-superior-to-clopidogrel/" title="Read more" >...</a>

Ticagrelor vs. Clopidogrel in ST elevation MI: Pros and cons

Platelet Inhibition in the PLATO study: insights from the ECG substudy. En el Estudio PLATO qued&oacute; evidenciado que el Ticagrelor disminuy&oacute; la mortalidad a 12 meses en comparaci&oacute;n con el Clopidogrel en el tratamiento de pacientes post-angioplast&iacute;a por un s&iacute;ndrome coronario agudo o por un cuadro estable (4,5 vs. 5,9%; P&lt;0.001). Estos resultados fueron del<a href="https://solaci.org/en/2011/01/01/ticagrelor-vs-clopidogrel-in-st-elevation-mi-pros-and-cons/" title="Read more" >...</a>

Top